Exchange: NASDAQ·Updated 07:30 PM EST

EVMN News

News
all
press releases
Evommune (NYSE:EVMN) Share Price Crosses Above 50-Day Moving Average - Here's Why
Evommune (NYSE:EVMN) Stock Crosses Above Fifty Day Moving Average - Should You Sell...
MarketBeat
Evommune (NYSE:EVMN) Share Price Crosses Above 50-Day Moving Average - Here's Why
Evommune (NYSE:EVMN) Stock Crosses Above Fifty Day Moving Average - Should You Sell...
MarketBeat
More News
Evommune, Inc. (NYSE:EVMN - Free Report) - Research analysts at HC Wainwright raised their FY2026 earnings per share (EPS) estimates for Evommune in a research report issued on Friday, November 13th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($3.28) per share for the...
MarketBeat
Evommune, Inc. (NYSE:EVMN - Get Free Report) has received a consensus rating of "Moderate Buy" from the sixteen analysts that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation...
MarketBeat
Wall Street Zen lowered shares of Evommune from a "sell" rating to a "strong sell" rating in a research report on Saturday...
MarketBeat
Evommune, Inc. (NYSE: EVMN) (the Company or Evommune), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a business update...
Business Wire
Pelthos Therapeutics Inc. (PTHS) delivered earnings and revenue surprises of -9.19% and -15.34%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Evommune, Inc. (NYSE: EVMN) (the Company or Evommune), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced presentations by management at the following upcoming investor conferences:Stifel Healthcare...
Business Wire
Evommune, Inc. (NYSE: EVMN) (Evommune or the Company), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that a pre-recorded webcast will be available at 8:30 a.m. E.T. today. On the webcast, President...
Business Wire
Evommune, Inc. (Evommune or the Company) (NYSE: EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 4,966,889 shares of its common...
Business Wire
Evommune, Inc. (NYSE: EVMN) (the Company or Evommune), a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases, and Hinova Pharmaceuticals Inc. (SSE: 688302) today announced an exclusive license agreement granting Evommune worldwide rights outside of Greater...
Business Wire

Advertisement|Remove ads.